Daniel Menkes is a Neurology physician affiliated with Oakland University. OpenAlex indexes 89 publications with 1,263 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3555 W 13 Mile Rd Ste N120
Royal Oak, MI 480736710
Telephone
855-863-8761Provider last certified this registry record 23 Oct 2020.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year202511 payments$11,004openpaymentsdata.cms.gov ↗
- Aucta Pharmaceuticals, Inc.Program year20252 payments
- LivaNova USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
55.3%Cholinesterase Inhibitor23.7%Pyridostigmine Bromide100%Part D<11 patientsSNRI11.6%Duloxetine Hcl100%Part D<11 patients+ 3 more classes in this area
Blood & clotting
14%Salt solutions14%Sodium Chloride100%Part D<11 patientsMusculoskeletal
13.5%Survival of Motor Neuron 2 Splicing Modifier13.5%Evrysdi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Targeting neuroinflammation in distal symmetrical polyneuropathy in diabetes
Drug Discovery Today
2024 - Conscientious Objection to Aggressive Interventions for Patients in a Vegetative State
The American Journal of Bioethics
2023 - Neonatal Fc Receptor Inhibitor Therapeutics in Neuromuscular Disease
Journal of Clinical Neuromuscular Disease
2023 - Pathogenesis underlying hexanucleotide repeat expansions in <i>C9orf72</i> gene in amyotrophic lateral sclerosis
Reviews in the Neurosciences
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Alon Kahana, MD
Oakland University
Mitchell Cappell, MD
Oakland University
Thomas Schwann, MD
Oakland University
Laith Jamil, MD
Oakland University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”